Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function.

ABSTRACT:

Background

Lung cancer is one of the most lethal cancers worldwide. Cisplatin, a widely used anti-lung cancer drug, has been limited in clinical application due to its drug resistance. Medicines targeting mitochondrial electron transport chain (ETC) complexes may be effective candidates for cisplatin-based chemotherapy.

Methods

In this study, the small molecule drug library from Food and Drug Administration FDA was used to screen for medicines targeting ETC. MTT and colony formation assays were used to investigate cell proliferation. Flow cytometry was employed to analyze cell cycle, apoptosis, reactive oxygen species (ROS), and mitochondrial membrane potential. Wound scratch and transwell assays were used to detect migration and invasion abilities. The activities of the ETC

SUBMITTER: Dong J 

PROVIDER: S-EPMC9108040 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature